Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetic Macular Edema
Interventions
Laser Photocoagulation, Intravitreal Aflibercept Injection
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
42
States / cities
Artesia, California • Beverly Hills, California • Mountain View, California + 38 more
Conditions
Retinal Vein Occlusion
Interventions
Ranibizumab 0.5mg (monthly), Ranibizumab 2.0mg (monthly), Pro re nata (prn) ranibizumab, Pro re nata (prn) Laser photocoagulation
Drug · Procedure
Lead sponsor
Peter A Campochiaro, MD
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab, Laser photocoagulation
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Completed Phase 3 Interventional Results available

Treatment for CI-DME in Eyes With Very Good VA Study

NCT01909791
Conditions
Diabetic Macular Edema
Interventions
Prompt Laser, Prompt aflibercept, Deferred laser, Deferred aflibercept
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
100
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 84 more
Conditions
Retinoblastoma
Interventions
Carboplatin, Maxitrol®, Focal Therapy, Plaque Radiotherapy
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Proliferative Diabetic Retinopathy
Interventions
Brolucizumab 6 mg, Panretinal photocoagulation laser
Biological · Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
40
States / cities
Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more
Conditions
Diabetic Macular Edema
Interventions
0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Conditions
Diabetic Macular Edema
Interventions
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation
Drug · Procedure
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 48 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

NCT01469156
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
ranibizumab 0.5 or 2.0 mg/0.05 cc
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Augusta, Georgia